Promising new combo tackles tough bone cancer

NCT ID NCT04067115

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested two drugs, trabectedin and irinotecan, in 37 people with a type of bone cancer called Ewing sarcoma that had come back or not responded to other treatments. The goal was to find a safe dose and see if the combination could shrink tumors. Participants also received a special PET scan to help measure the treatment's effect.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital / Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Children's Hospital of Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • National Cancer Institute

    Bethesda, Maryland, 20892, United States

  • University of Michigan

    Ann Arbor, Michigan, 48106, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19105, United States